Supernus Offers Business Update: Reaffirms Does Not Need Added Capital, Will 'Explore a Broad Range of Strategic Opportunities'

Supernus Pharmaceuticals, Inc.

is providing the following business update in light of recent investor filings with the SEC: * The Company reaffirms that it is on track to become cash flow breakeven by year-end, with a year-end cash balance of $75 million - $85 million. * The Company reaffirms that it does not need to raise additional capital to reach profitability. It expects to be profitable starting in 2014 and beyond. * The Company reaffirms that it expects revenues of approximately $105 million in 2014. The Company is focused on executing its current strategy as outlined below to maximize shareholder value. Drive growth in its epilepsy portfolio of products, Trokendi XR^® and Oxtellar XR^®. The products, successfully launched last year, are in their early stage of growth, with total peak sales potential of $400 million to $500 million. The Company continues to strengthen its intellectual property position on both products with four patents covering Oxtellar XR and three patents covering Trokendi XR with expiry that is no earlier than 2027. Additional patent applications are in process to ensure that the products are covered by the full scope of patent protection to which they are entitled. Demonstrate significant progress in the development of our pipeline. This is evident by the recent FDA fast track designation on SPN-810 and the selection of the sustained release formulation on SPN-812. The Company has also completed significant work on: the development and manufacturing of the active drug substance; development and manufacturing of product formulations, and preclinical testing including two year carcinogenicity and several toxicology studies. The Company's pipeline targets markets with significant commercial potential. SPN-810 is expected to be the first product approved for impulsive aggression that is prevalent across many CNS disorders including ADHD, autism, bipolar, and schizophrenia, and for which there are currently no approved products on the market. Similarly, SPN-812 is expected to have a differentiated clinical profile compared to other non-stimulants for the treatment of ADHD. Both products have successfully progressed and have completed multiple trials leading to the planned 2015 start of patient dosing in Phase III for SPN-810 and patient dosing in Phase IIb for SPN-812. The Company is also building a broad portfolio of patents to provide strong intellectual property protection on both products. Explore a broad range of strategic opportunities. This includes in-licensing products and entering into co-promotion partnerships which are synergistic with our neurology sales force call point, potential co-development partnerships on our pipeline products, and growth opportunities through value-creating and transformative merger and acquisition transactions.